Professor, Hematology and Medical Oncology, Emory University School of Medicine
Hematology
Dr. Sagar Lonial, MD
|
|
Give Review
Sagar Lonial is an expert in the field of Hematology. He went to medical school at University of Louisville School of Medicine. University of Louisville School of Medicine is ranked 83/0 in Research/PrimaryCare. Sagar Lonial, MD has written publications. He has 44 publications published with PubMed. The lastest paper is: 'Treatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.' He is registered with Medicare.
Publications
- Central nervous system involvement by multiple Myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple Myeloma: outcomes by prior treatment.
- 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
- A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgki...
- Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
- Panobinostat for the treatment of relapsed or relapsed/refractory multiple Myeloma: pharmacology and clinical outcomes.
- How I treat high risk Myeloma.
- Monoclonal antibodies in the treatment of multiple Myeloma: Current status and future perspectives.
- New Cancers after autotransplantations for multiple myeloma.
- Safety and tolerability of ixazomib, an Oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple my...
- International Myeloma Working Group updated criteria for the diagnosis of multiple Myeloma.
- Predictors of survival outcomes in phase 1 relapsed or refractory multiple Myeloma patients.
- Relapsed and Refractory Multiple Myeloma: New Therapeutic Strategies.
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple Myeloma: ...
- Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell Lymphoma.
- Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation.
- Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth.
- Pharmacoeconomic Analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
- Phase 1 study of twice-weekly dosing of investigational oral proteasome inhibitor ixazomib in patients with relapsed and/or refractory multiple Myeloma.
- MLN4924, an investigational NAE inhibitor, suppresses AKT and mTOR signaling pathway through up regulating REDD1 in human myeloma Cells.
- Second transplants for multiple Myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation.
- Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex.
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-Analysis of individual patient data.
- A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory Myeloma.
- Elotuzumab : a novel anti-CS1 monoclonal antibody for the treatment of multiple Myeloma.
- Consolidation and maintenance therapy with lenalidomide, bortezomib, dexamethasone (RVD) in high-risk Myeloma patients.
- Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic Cell transplants from partially mismatched unrelated donors.
- Non-secretory Myeloma: a clinician's guide.
- Temporal changes in plerixafor administration and hematopoietic stem Cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
- Bortezomib-containing induction regimens in transplant-eligible myeloma patients: A meta-Analysis of phase 3 randomized clinical trials.
- Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma.
- Association of response endpoints with survival outcomes in multiple Myeloma.
- Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulati...
- Relapsed and refractory lymphoid neoplasms and multiple Myeloma with a focus on carfilzomib.
- A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with Lymphoma.
- Induction therapy for newly diagnosed multiple Myeloma.
- Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.
- Early clearance of peripheral blood blasts predicts response to induction chemotherapy in Acute myeloid leukemia.
- A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lym...
- Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation.
- Emerging treatments in Castleman Disease - a critical appraisal of siltuximab.
- Integrated Analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma.
- Treatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Schools
University of Louisville School of Medicine
Baylor College Of Med
Emory University School Of Med
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Emory University -
Baylor College of Medicine -
University of Louisville School of Medicine
Hospital
-
Emory University Hospital -
Emory University Hospital Midtown -
Grady Memorial Hospital
Drug Facts
| NPI NUMBER | 1487762118 | |
| NPPES Provider LastName | LONIAL | |
| NPPES Provider FirstName | SAGAR | |
| NPPES Provider ZIPCode | 303221013 | |
| NPPES Provider State | GA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1661.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 191.0 | |
| Percent Opioid Claims | 11.5 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487762118 |
| Last Name Of The Provider | LONIAL |
| First Name Of The Provider | SAGAR |
| View All |
Similar Doctors
|
|
Dr. Richard C. Lauer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sahar E. Rosenbaum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pradeep C. Jolly, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Douglas C. Collins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joan H. Weens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ajay K. Nooka, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Duc Q. Tran Jr., MD |
|
|
Linsheng Zhang, MB CHB |
|
|
Dr. Robert L. Stahl, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Linda Ballard, CPNP |
|
|
Robin Pitts, CFNP |